

Viessia; Vinilex; **Neth.:** Navelbine; **Norw.:** Navelbine; **NZ:** Navelbine; **Philipp.:** Navelbine; Vinotel; **Pol.:** Navelbine; Navirel; **Port.:** Navelbine; Vinorel; **Rus.:** Mavexex (Мавеекс); Navelbine (Навельбин); **S.Afr.:** Navelbine; **Singapore:** Navelbine; **Spain:** Navelbine; **Swed.:** Navelbine; **Switz.:** Navelbine; **Thai.:** Navelbine; Vinelbine; **Turk.:** Navelbine; **UK:** Navelbine; **USA:** Navelbine.


Vorinostat (USAN, rINN)

SAHA; Suberoylanilide Hydroxamic Acid; Vorinostatium. *N*-Hydroxy-*N'*-phenyl octanediamide.

Вориноста́т

$C_{14}H_{20}N_2O_3 = 264.3$.

CAS — 149647-78-9.



Adverse Effects, Treatment, and Precautions

For general discussions see Antineoplastics, p.635, p.639, and p.641.

The most common adverse effects of vorinostat are gastrointestinal disturbances, fatigue, chills, dry mouth and taste disorders. Thrombocytopenia and anaemia also occur commonly, and are dose-related; dose reductions may be necessary and in some instances, therapy may need to be stopped. Pulmonary embolism has occurred. Other adverse effects include muscle spasms, alopecia, dizziness, peripheral oedema, headache, pruritus, cough, upper respiratory-tract infection, and pyrexia. Hypokalaemia and hyperglycaemia have been reported, as has prolongation of the QT interval. Blood cell counts, electrolytes, glucose, and serum creatinine should be monitored every 2 weeks during the first 2 months of therapy and monthly thereafter. Baseline and periodic ECG monitoring should be performed.

Interactions

Severe thrombocytopenia and gastrointestinal bleeding have been reported when vorinostat has been given with other histone deacetylase inhibitors such as valproic acid; platelet counts should be monitored every 2 weeks for the first 2 months of therapy. Vorinostat may prolong prothrombin time and affect the INR in patients receiving coumarin anticoagulants.

Pharmacokinetics

After an oral dose of vorinostat with a high-fat meal, mean time to maximum plasma concentration was about 4 hours; this was reduced to 1.5 hours after fasting. Aside from this decrease in the rate of absorption, a high-fat meal also increased the extent of absorption. While these results were stated not to be clinically significant, licensed product information recommends that vorinostat be taken with food. Plasma protein binding is about 71%. Vorinostat is metabolised by glucuronidation and hydrolysis followed by oxidation; metabolites are pharmacologically inactive. Less than 1% of a dose is recovered in the urine as unchanged drug. The mean terminal half-life is about 2 hours for vorinostat.

References.

- Rubin EH, *et al.* A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. *Clin Cancer Res* 2006; **12**: 7039–45.

Uses and Administration

Vorinostat is a histone deacetylase inhibitor used for the treatment of cutaneous T-cell lymphoma (see Non-Hodgkin's Lymphomas, p.656). The recommended dose is 400 mg orally, given once daily with food. This may be reduced to 300 mg once daily, with a further reduction to 300 mg once daily for 5 consecutive days of each week, if needed. Treatment may be continued as

long as there is no evidence of progressive disease or unacceptable toxicity.

Vorinostat is also under investigation for the treatment of multiple myeloma and mesothelioma.

References.

- O'Connor OA. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. *J Clin Oncol* 2006; **24**: 166–73.
- Krug LM, *et al.* Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. *Clin Lung Cancer* 2006; **7**: 257–61.
- Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. *Br J Cancer* 2006; **95** (suppl): S2–S6.
- O'Connor OA. Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. *Br J Cancer* 2006; **95** (suppl): S7–S12.
- Duvic M, Zhang C. Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. *Br J Cancer* 2006; **95** (suppl): S13–S19.
- Anonymous. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma. *Med Lett Drugs Ther* 2007; **49**: 23–4.

Preparations

Proprietary Preparations (details are given in Part 3)

USA: Zolinza.

Vorozole (BAN, USAN, rINN) ⓧ

R-83842; Vorozol; Vorozolum. (+)-6-[4-Chloro- α -(1,2,4-triazol-1-yl)benzyl]-1-methyl-1*H*-benzotriazole.


Ворозо́л

$C_{16}H_{13}ClN_6 = 324.8$.

CAS — 129731-10-8.

ATC — L02BG05.

ATC Vet — QL02BG05.



Profile

Vorozole is a selective nonsteroidal inhibitor of the aromatase (oestrogen synthetase) system. It has been investigated in the treatment of breast cancer.

References.


- Goss PE, *et al.* Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. *J Clin Oncol* 1999; **17**: 52–63.
- Harper-Wynne CL, *et al.* Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. *J Clin Oncol* 2002; **20**: 1026–35.

Zinostatatin (USAN, rINN)

Neocarzinostatatin; NSC-69856; NSC-157365; Zinostatina; Zinostatine; Zinostatatinum.

Зиноста́тин

CAS — 9014-02-2.



Description. Zinostatatin is an antineoplastic antibiotic obtained from *Streptomyces carzinostaticus*.

Pharmacopoeias. *Jpn* includes zinostatatin stimalamer.

Profile

Zinostatatin is an antibiotic with antineoplastic activity and has been used in the treatment of malignant neoplasms.

Zinostatatin stimalamer (SMANCS), a conjugate of zinostatatin with a styrene-maleic acid polymer, is used for the treatment of liver cancer.

Zorubicin Hydrochloride (USAN, rINNM)

Hydrocloruro de zorubicina; NSC-164011; RP-22050 (zorubicin); Zorubicine, Chlorhydrate de; Zorubicini Hydrochloridum. Benzoic acid (2*S*-cis)-{1-[4-(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyloxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxonaphthalen-2-yl]ethylidene}hydrazide hydrochloride.


Зору́бичина Гидрохлори́д

$C_{34}H_{35}N_3O_{10} \cdot HCl = 682.1$.

CAS — 54083-22-6 (zorubicin); 36508-71-1 (zorubicin hydrochloride).

ATC — L01DB05.

ATC Vet — QL01DB05.



(zorubicin)

Profile

Zorubicin is an anthracycline antibiotic with antineoplastic actions similar to those of doxorubicin (see p.712). It has been used as the hydrochloride in the treatment of acute leukaemias.

rhoea. There appear to be no important differences in the efficacy of antimuscarinics for Parkinson's disease but some patients may tolerate one drug better than another. Those commonly used for Parkinson's disease include *benzotropine*, *orphenadrine*, *procyclidine*, and *trihexyphenidyl*.

- *Amantadine* is a weak dopamine agonist with some antimuscarinic activity although its activity as an antagonist of *N*-methyl-D-aspartate may also have a beneficial effect in Parkinson's disease. It has mild antiparkinsonian effects compared with levodopa but is relatively free from adverse effects. It can improve bradykinesia as well as tremor and rigidity but only a small proportion of patients derive much benefit. It is used similarly to antimuscarinics in early disease when symptoms are mild, but tolerance to its effects can occur rapidly.

Choice and implementation of drug treatment. If symptoms are mild, drug therapy may not be required in the early stages of the disease. When symptoms become troublesome but are still relatively mild *amantadine* or an *antimuscarinic* may be started; antimuscarinics are useful when tremor predominates but are generally more suitable for younger patients and in drug-induced rather than idiopathic parkinsonism. Some have begun treatment with *selegiline* immediately, but there have been doubts over whether it has a neuroprotective effect, as postulated, and also over long-term safety. There is no consensus on when to start dopaminergic treatment or whether to begin with *levodopa* or a *dopamine agonist*. For most patients treatment with levodopa eventually becomes necessary, but many neurologists delay initial treatment with levodopa because of the increased risk of motor complications. New patients, especially younger patients, therefore often begin treatment with a dopamine agonist, with levodopa reserved for the elderly, the frail, or those with intercurrent illness or more severe symptoms.

When levodopa does become necessary, the usual practice is to start with small doses, together with a peripheral dopa-decarboxylase inhibitor, and increase slowly to a dose which reduces disability to an acceptable level. Variations in response and diminishing effectiveness over the years necessitate careful adjustment of the size and form of the dose and the dosage schedule.

Complications of treatment. Fluctuations in mobility have been reported in more than half of patients on levodopa after 5 years of therapy. They generally proceed through predictable 'end-of-dose' deterioration to the 'on-off' phenomenon with marked very sudden swings from mobility to immobility. The cause of the fluctuations is not known, but multiple factors including desensitisation of dopamine receptors, interference with the response to dopamine by other levodopa metabolites such as 3-*O*-methyldopa, fluctuating plasma concentrations, and erratic transport of levodopa from blood to the brain have been suggested. It appears that as the disease progresses the capacity of the nigrostriatal dopaminergic system to synthesise and store dopamine, and to act as a buffer in maintaining dopamine brain concentrations, declines. Dopamine concentrations therefore become more dependent on levodopa dosage and the pattern of response will come to reflect more closely the rise and fall in levodopa concentrations. Eventually the effect of various factors that produce even small changes in plasma concentrations of levodopa will progressively become more pronounced.

Approaches to the management of 'end-of-dose' fluctuations include more frequent but smaller doses and the use of modified-release preparations. Addition of *selegiline* or partial replacement of levodopa by a dopamine agonist with a more prolonged action may also be tried.

Various attempts have been made to overcome the 'on-off' phenomenon. Those speculating that long-term treatment results in altered dopamine receptor sensitivity have used controlled withdrawal of levodopa for short periods ('drug holidays') but it is a dangerous procedure of doubtful value and no longer recommended.

Others have linked the 'on-off' phenomenon to variable plasma concentrations although, since transfer of levodopa into the brain involves active transport mechanisms, concentrations in plasma may not necessarily reflect those in the brain. Continuous intraduodenal or intravenous infusion of levodopa has been shown to reduce fluctuations in mobility, which suggests that dopamine receptors are still sensitive, although this is not practical for day-to-day man-

agement (but see below). However, there is evidence that some patients may benefit from modified-release formulations of levodopa with a peripheral dopa-decarboxylase or COMT inhibitor. As levodopa competes with amino acids for uptake into the brain, attempts to lessen fluctuations in dopamine brain concentrations have included taking levodopa on an empty stomach and also delaying most of a day's protein consumption until the evening. Addition of entacapone, rasagiline, selegiline, or a dopamine agonist may also help to reduce 'on-off' phenomena. If fluctuations remain a problem subcutaneous apomorphine is often effective. In some countries a gel formulation of levodopa with carbidopa is available for continuous infusion by an ambulatory pump into the duodenum when other available combination therapy has not been satisfactory.

Other complications of treatment with levodopa can include **dyskinesia**, which may respond to dosage adjustment or partial replacement of levodopa with a dopamine agonist. *Amantadine* may also be considered, although evidence is lacking. Some patients with Parkinson's disease may experience **severe pain and dystonia**; measures to increase 'on' periods can help reduce or eliminate pain in most patients.

Patients with Parkinson's disease can suffer from a range of **psychiatric effects**, such as depression, dementia, sleep disturbances, and psychosis, due to the adverse effects of drug therapy and to disease progression. It has been recommended that if patients develop psychotic reactions, an attempt to adjust their antiparkinsonian drugs should be tried before resorting to the use of antipsychotics. Although classical antipsychotics are usually contra-indicated because they can exacerbate parkinsonism, the atypical antipsychotics clozapine and quetiapine may be used in treatment-resistant psychosis—see Disturbed Behaviour, p.954. The cholinesterase inhibitor *rivastigmine* is licensed in some countries for the symptomatic treatment of mild to moderately severe dementia in Parkinson's disease. **Excessive daytime sleepiness and sudden onset of sleep** have been reported with dopamine agonists and patients should be warned of the possible risks (see Effects on Mental Function, under Adverse Effects of Levodopa, p.805). **Fibrotic reactions** resulting in cardiovascular and pulmonary adverse effects have been reported with ergot derivatives and patients should be monitored (see Fibrosis, under Adverse Effects of Bromocriptine, p.799). **Nausea and vomiting** induced by dopaminergics may be minimised by introducing the drug gradually and giving the dose with food, but if this is ineffective or apomorphine is being used these effects can be controlled by the antiemetic domperidone. Domperidone does not readily cross the blood-brain barrier and therefore acts mainly as a peripheral dopamine antagonist. Tolerance to the nausea usually develops after a few weeks and domperidone may then be withdrawn.

References.

- Quinn N. Drug treatment of Parkinson's disease. *BMJ* 1995; **310**: 575–9.
- Harder S, et al. Concentration-effect relationship of levodopa in patients with Parkinson's disease. *Clin Pharmacokinet* 1995; **29**: 243–56.
- Giron LT, Koller WC. Methods of managing levodopa-induced dyskinesias. *Drug Safety* 1996; **14**: 365–74.
- Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? *Mayo Clin Proc* 1996; **71**: 659–70.
- Mendis T, et al. Drug-induced psychosis in Parkinson's disease: a review of management. *CNS Drugs* 1996; **5**: 166–74.
- Hughes AJ. Drug treatment of Parkinson's disease in the 1990s. *Drugs* 1997; **53**: 195–205.
- Gottwald MD, et al. New pharmacotherapy for Parkinson's disease. *Ann Pharmacother* 1997; **31**: 1205–17.
- Lang AE, Lozano AM. Parkinson's disease. *N Engl J Med* 1998; **339**: 1044–53 and 1130–43.
- Bhatia K, et al. Guidelines for the management of Parkinson's disease. *Hosp Med* 1998; **59**: 469–80.
- Ahlskog JE. Medical treatment of later-stage motor problems of Parkinson disease. *Mayo Clin Proc* 1999; **74**: 1239–54.
- Anonymous. Developments in the treatment of Parkinson's disease. *Drug Ther Bull* 1999; **37**: 36–40.
- Olanow CW, et al. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. *Neurology* 2001; **56** (suppl 5): S1–S88.
- Miyasaki JM, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. *Neurology* 2002; **58**: 11–17.
- Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. *Lancet* 2002; **360**: 1767–9.
- Deleu D, et al. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. *Clin Pharmacokinet* 2002; **41**: 261–309.
- Korczyn AD, Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. *Drugs* 2002; **62**: 775–86.
- Rascol O, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. *Lancet* 2002; **359**: 1589–98.

- Katzschlager R, et al. Anticholinergics for symptomatic management of Parkinson's disease. Available in The Cochrane Database of Systematic Reviews; Issue 3. Chichester: John Wiley; 2002 (accessed 16/02/06).
- Deane KHO, et al. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Available in The Cochrane Database of Systematic Reviews; Issue 4. Chichester: John Wiley; 2004 (accessed 16/02/06).
- Schapiro AHV, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. *JAMA* 2004; **291**: 358–64.
- Samii A, et al. Parkinson's disease. *Lancet* 2004; **363**: 1783–93.
- Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. *Postgrad Med J* 2004; **80**: 452–8.
- Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. *Neurology* 2004; **62** (suppl 1): S56–S63.
- Barone P, et al. Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. *Neurology* 2004; **63** (suppl 3): S35–S38.
- Goetz CG, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease—2001 to 2004. *Mov Disord* 2005; **20**: S23–39.
- Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. *Clin Pharmacokinet* 2006; **45**: 109–36.
- Suchowersky O, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006; **66**: 968–75. Also available at: <http://www.neurology.org/cgi/reprint/66/7/968.pdf> (accessed 11/08/08).
- Suchowersky O, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006; **66**: 976–82. Correction. *ibid.*; **67**: 299.
- Pahwa R, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006; **66**: 983–95. Also available at: <http://www.neurology.org/cgi/reprint/66/7/983.pdf> (accessed 11/08/08).
- Miyasaki JM, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006; **66**: 996–1002. Also available at: <http://www.neurology.org/cgi/reprint/66/7/996.pdf> (accessed 11/08/08).
- Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. *Neurology* 2006; **66** (suppl 4): S69–S79.
- Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. *Neurology* 2006; **67** (suppl 2): S30–S38.
- National Collaborating Centre for Chronic Conditions/NICE. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care (issued June 2006). Available at: <http://www.nice.org.uk/nicemedia/pdf/cg035fullguideline.pdf> (accessed 05/06/08).
- Clarke CE. Parkinson's disease. *BMJ* 2007; **335**: 441–5.
- Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. *Neurology* 2007; **69**: 1701–11.
- Davie CA. A review of Parkinson's disease. *Br Med Bull* 2008; **86**: 109–27.
- Stowe RL, et al. Dopamine agonist therapy in early Parkinson's disease. Available in The Cochrane Database of Systematic Reviews; Issue 2. Chichester: John Wiley; 2008 (accessed 05/06/08).

Amantadine (BAN, pINN)

Amantadini; Amantadin; Amantadina; Amantadinum. Tricyclo[3.3.1.1^{3,7}]dec-1-ylamine.


Амантадин

C₁₀H₁₇N = 151.2.

CAS — 768-94-5.

ATC — N04BB01.

ATC Vet — QN04BB01.



Amantadine Hydrochloride (BANM, USAN, pINN)

1-Adamantanamine Hydrochloride; Amantadinihydrokloridi; Amantadine, chlorhydrate d'; Amantadin-hidrokloridi; Amantadin-hydrochlorid; Amantadinihydroklorid; Amantadini hydrochloridum; Amantadino hidrochloridas; EXP-105-I; Hidrochloruro de amantadina; NSC-83653. Tricyclo[3.3.1.1^{3,7}]dec-1-ylamine hydrochloride.

Амантадина Гидрохлорид

C₁₀H₁₇N.HCl = 187.7.

CAS — 665-66-7.

ATC — N04BB01.

ATC Vet — QN04BB01.